Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD19

CD19

Brief Information

Name:B-lymphocyte antigen CD19
Target Synonym:Differentiation antigen CD19,CD19 Molecule,B-Lymphocyte Surface Antigen B4,CD19 Antigen,B-Lymphocyte Antigen CD19,CVID3,B4,Antigens, CD19,CD19,T-cell surface antigen Leu-12
Number of Launched Drugs:10
Number of Drugs in Clinical Trials:279
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CD19 mAb - 01 PCC AutoImmunity,Hematological Malignancy Blood tumor,Autoimmune disease

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
CD19 mAb Monospecific antibody Immunological disease autoimmune disease IND Global
PEGylation CD3 + CD19 bsAb Monospecific antibody Immunological disease Immunodeficiencies IND Global

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CHEK-ATP003 Human HEK293/Human CD19 Stable Cell Line
MBS-C002 Human ActiveMax® Human CD19 μBeads, premium grade (for cells)
HGS-S259 Rabbit Recombinant Monoclonal Anti-CD19 Antibody, Rabbit (4A6)
CD9-HA2H3 Human Alexa Fluor™ 488-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H3-structure
CD9-HA2H6 Human Alexa Fluor™ 647-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H6-structure
CD9-H82F6 Human Biotinylated Human CD19 (20-291) Protein, Fc,Avitag™, premium grade
CD9-H82F6-structure
CD9-H82F6-sds
CD9-M52H8 Mouse Mouse CD19 Protein, His Tag
CD9-M52H8-structure
CD9-M52H8-sds
CD9-HA2H7 Human Alexa Fluor™ 555-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H7-structure
CD9-HA2H5 Human APC-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation)
CD9-HA2H5-structure
CHEK-ATS056 Human HEK293/Human Anti-CD19 Stable Cell Line
CD9-HA2H9 Human APC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HA2H9-structure
CD9-HP2H5 Human PE-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HP2H5-structure
CD9-R52H6 Rat Rat CD19 Protein, His Tag
CD9-R52H6-structure
CD9-R52H6-sds
CD9-C52H4 Canine Canine CD19 Protein, His Tag
CD9-C52H4-structure
CD9-C52H4-sds
CD9-R52H3 Rabbit Rabbit CD19 Protein, His Tag
CD9-R52H3-structure
CD9-R52H3-sds
CD9-HF2H3 Human FITC-Labeled Human CD19 (20-291) Protein, His TagStar Staining
CD9-HF2H3-structure
CD9-HF2H3-sds
CD9-C5221 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, His Tag
CD9-C5221-structure
CD9-C5221-sds
MBS-K005 Human Human CD19-coupled Magnetic Beads
CD9-H82E9 Human Biotinylated Human CD19 (20-291) Protein, His,Avitag™, premium grade
CD9-H82E9-structure
CD9-H82E9-sds
CD9-HP2H3 Human PE-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation)
CD9-HP2H3-structure
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag (MALS verified)
CD9-H5258-structure
CD9-H5258-sds
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein, His Tag
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, premium grade
CD9-H5251-structure
CD9-H5251-sds
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag
CD9-H52H2-structure
CD9-H52H2-sds
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H8259 Human Biotinylated Human CD19 Protein, Fc Tag, ultra sensitivity (primary amine labeling)
CD9-H8259-structure
CD9-H8259-sds
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds
ACRO Quality

Part of Bioactivity data

CD9-HA2H3-Cell-based assay
 CD19 CAR_T

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 10 μg/mL of AF488-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).

CD9-H82E9-SPR
 CD19 SPR

Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested).

CD9-H5251-SPR
 CD19 SPR

Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) captured on CM5 chip via Anti-Human lgG Fc antibodies surface, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.17 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CD19,B4,CVID3,MGC12802

Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Axicabtagene ciloleucel FKC-876; KTE-C19; KTE C19 Approved Cabaret Biotech, Gilead Sciences Inc Yescarta, 奕凯达 United States Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, B-Cell Kite Pharma Eu Bv 2017-10-18 Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
Tafasitamab XENP-5574; MOR-00208; XmAb-5574; MOR-208 Approved Xencor Inc MONJUVI, Minjuvi United States Lymphoma, Large B-Cell, Diffuse Morphosys Us Inc 2020-07-31 Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hemic and Lymphatic Diseases; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Blinatumomab MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 Approved Amgen Inc Blincyto, 倍利妥 United States Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Amgen Inc 2014-12-03 Neoplasm, Residual; Leukemia, Myelogenous, Chronic; Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Tisagenlecleucel LG-740; CART-019; CTL-019; CART-19 Approved Novartis Pharma Ag, University Of Pennsylvania Kymriah United States Precursor Cell Lymphoblastic Leukemia-Lymphoma Novartis Pharmaceuticals Corp 2017-08-30 Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
Inaticabtagene Autoleucel CNCT19; CNCT-19; HY001 Approved Juventas Cell Therapy Ltd 源瑞达 Mainland China Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Juventas Cell Therapy Ltd 2023-11-08 Hematologic Neoplasms; Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
Inebilizumab VIB-0551; 16C4-aFuc; MEDI-551; MT-0551 Approved Duke University, Horizon Therapeutics PLC Uplinza, Uplizna, ユプリズナ United States Neuromyelitis Optica Viela Bio Inc 2020-06-11 Hematologic Neoplasms; Myasthenia Gravis; Lymphoma, B-Cell; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Encephalitis Details
Brexucabtagene autoleucel KTE-X19; FKC-889 Approved Kite Pharma Inc, Gilead Sciences Inc Tecartus United States Lymphoma, Mantle-Cell Kite Pharma Inc 2020-07-24 Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Relmacabtagene autoleucel JWCAR-029 Approved Suzhou Yaomingjunuo Biotechnology Co Ltd 倍诺达, Carteyva Mainland China Lymphoma, Large B-Cell, Diffuse Jw Therapeutics (Shanghai) Co Ltd 2021-09-01 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Lisocabtagene maraleucel Liso-Cel; JCAR-017 Approved Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics Inc, Seattle Children'S Research Institute Breyanzi United States Lymphoma, Large B-Cell, Diffuse Bristol-Myers Squibb Company 2021-02-05 Lymphoma, B-Cell; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Mediastinal Neoplasms; Immune System Diseases; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Loncastuximab tesirine ADCT-402; MT-2111 Approved Adc Therapeutics Sa ZYNLONTA, Lonca United States Lymphoma, Large B-Cell, Diffuse Adc Therapeutics Sa 2021-04-23 Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
4G7SDIE Clinical Synimmune Gmbh, University Of Tubingen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) Phase 1 Clinical University Hospitals Cleveland Medical Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical The University Of Texas Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
ThisCART-19 ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B Phase 2 Clinical Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
aCD19z aCD19z Phase 1 Clinical Christie Hospital Nhs Foundation Trust Lymphoma, Non-Hodgkin Details
PTG-01 PTG-01 Phase 1 Clinical Protheragen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
TC-110 TC-110 Phase 2 Clinical Tcr2 Therapeutics Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
pCAR-19B Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
H-31970-SAGAN H-31970-SAGAN Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Phase 3 Clinical Chaim Sheba Medical Center At Tel Hashomer Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-19 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse Details
CD19 CAR-T (HuaDao CAR-Tcell) Phase 2 Clinical Huadao (Shanghai) Biopharma Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
OnCARlytics(Imugene) CF-33-CD-19 Phase 1 Clinical City Of Hope National Medical Center, Imugene Ltd Solid tumours Details
GC-022 GC-022; GC-022F Phase 2 Clinical Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19-CART (Unicar-Therapy Bio-medicine Technology) Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Persongen Biotherapeutics Details
CD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina) Phase 2 Clinical Medical University Of South Carolina Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Candidiasis, Vulvovaginal; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) Phase 3 Clinical Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) Phase 2 Clinical Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell Details
Anti-BCMA/CD19 CAR-T Therapy(University College London) Phase 1 Clinical University College London Multiple Myeloma Details
BCN-CP01 BCN-CP01; BCN CP01; BCN-CP-01; GLPG5201; GLPG-5201 Phase 2 Clinical CellPoint BV Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 Autologous CAR-T Cell therapy (920th Hospital) OlyCAR-019 Phase 2 Clinical The 920th Hospital Of Joint Logistics Support Force Of PLA Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 2 Clinical Shanghai Ultra-T Immune Therapeutics Co LTD Leukemia, B-Cell Details
TBI-2001 TBI-2001 Phase 1 Clinical University Health Network, Takara Bio Inc Lymphoma, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Metabolically Armed CD19 CAR-T cells(Leman Biotech) Meta10-19 Phase 1 Clinical Leman Biotech Co Ltd, Anhui Provincial Hospital Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
4SCAR19U T Cells Therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR19U cells Phase 1 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Candidiasis, Vulvovaginal; Neoplasm, Residual; Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Lymphoma, B-Cell Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
XYF19 CAR-T Cell Therapy XYF-19 Phase 1 Clinical Guangzhou Yinming Biomedical Technology Co Ltd, Xi'An Yufan Biotechnology Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
huCART19-IL18 Phase 1 Clinical University Of Pennsylvania, Kite Pharma Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Takara Bio Inc Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia Details
Virus-specific-CD19.CAR Phase 1 Clinical Baylor College Of Medicine Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD Phase 1 Clinical University College London Central Nervous System Lymphoma Details
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
CD19.CAR-VST CD19.CAR-VST Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
C-CAR011 Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
CD19-CAR(The University Of Texas MD Anderson Cancer Center) Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia; Lymphoma Details
CD19 CAR-T cell therapy (Chongqing Precision Biotech) MC-1-50 Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Lymphoma, B-Cell; Leukemia; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Dermatomyositis; Lymphoma, Large B-Cell, Diffuse; Sjogren's Syndrome; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rapcabtagene autoleucel YTB-323 Phase 2 Clinical Novartis Pharma Ag Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Evoncabtagene pazurgedleucel CTX-110 Phase 2 Clinical Crispr Therapeutics Ag Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) Tongji University Details
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) ORGCAR19; ORGCAR-19 Phase 2 Clinical Kecellitics Biotech Company Ltd Lymphoma, B-Cell; Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) Clinical Leidos Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) PL-001 Phase 2 Clinical Pell Bio-Med Technology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
PCAR-019 (Anke Biotechnology) Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
A-319 A-319 Phase 1 Clinical Evive Biotech Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CB-010 Phase 1 Clinical Caribou Biosciences Inc Lymphoma, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) Phase 2 Clinical Federal Research Institute of Pediatric Hematology Oncology and Immunology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University, Orca Biosystems Inc Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Prizloncabtagene autoleucel (AbelZeta Pharma) C-CAR039; C-CAR-039; C CAR 039; EXP-039 Phase 2 Clinical Cellular Biomedicine Group Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
JCAR-014 JCAR-014; JCAR021 Phase 2 Clinical Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CABA-201 CABA-201 Phase 2 Clinical Cabaletta Bio Inc Myasthenia Gravis; Myositis; Dermatomyositis; Autoimmune Diseases; Scleroderma, Systemic; Lupus Nephritis; Lupus Erythematosus, Systemic; Muscular Diseases Details
Varnimcabtagene autoleucel ARI-0001; IMN-003A; IMN-003-A Phase 2 Clinical Hospital Clínic De Barcelona, Institut D'Investigacions Biomèdiques August Pi I Sunyer Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) Massachusetts General Hospital Details
Anti-human CD19-CD22 T cell therapy Phase 1 Clinical Hrain Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) Phase 2 Clinical Hematologic Diseases; Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Uppsala University) Phase 2 Clinical Uppsala University Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics) ICG140 iCell Gene Therapeutics LLC Details
SC-291 SC-291 Phase 1 Clinical Sana Biotechnology Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
HuCART19 Phase 2 Clinical National Cancer Institute, Kite Pharma Lymphoma, B-Cell; Rejection of renal transplantation; Renal Insufficiency; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Kidney Failure, Chronic Details
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) Phase 2 Clinical The First Affiliated Hospital Of Soochow University, Suzhou University Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) Phase 2 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19-CAR T cells (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Leukemia Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase 1 Clinical Nagoya University, Shinshu University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-CD19 T cell therapy Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
AMG-562 AMG-562 Phase 1 Clinical Amgen Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Clinical Pinze Lifetechnology Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
CLIC-1901 (Ottawa Hospital Research Institute) CLIC-1901 Phase 2 Clinical Ottawa Hospital Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Obexelimab XmAb-5871; AMG-729 Phase 3 Clinical Xencor Inc Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) Phase 1 Clinical Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
TanCART19/20 Phase 1 Clinical Pla General Hospital Neuromyelitis Optica Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
NCAR19-T Phase 2 Clinical Second Military Medical University Of Chinese People'S Liberation Army Lymphoma, B-Cell Details
AZD-0486 TNB-486; AZD-0486; AZD0486 Phase 2 Clinical Teneobio Inc, Astrazeneca Plc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
GC-007g GC007g; GC-007g Phase 2 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
IM19CAR-T IM19 Phase 2 Clinical Beijing Yimiao Medical Technology Co Ltd Leukemia; Hematologic Neoplasms; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma Details
UTAA-09 cells therapy UTAA-09; UTAA09; UTAA09/17γδT; UTAA 09/17 Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd, Anhui Provincial Hospital Lymphoma, B-Cell Details
CLN-978 CLN-978 Phase 1 Clinical Adimab LLC Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
GC-007F (Gracell Biotechnology) GC-007F Phase 1 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 directed CAR T cell therapy (University of Colorado) Phase 1 Clinical University Of Colorado Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD70 NK cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR NK Cell therapy(Enricnk) KN5501; KN-5501 Phase 1 Clinical Changhai Hospital Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) SENL-B19 Phase 2 Clinical Leukemia; Lymphoma, B-Cell; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma Details
QH-103 Cell Therapy QH-103 Phase 1 Clinical Anhui Provincial Hospital Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) CAR-NK-CD19 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) Phase 2 Clinical New York Medical College Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Kostmann Syndrome; Anemia, Sickle Cell Details
CD19 Universal CAR-γδ T Cells Therapy(Guangzhou Bio-Gene Technology) Phase 2 Clinical Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital Lupus Erythematosus, Systemic Details
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) yinnuokati-19 Phase 2 Clinical Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) XLCART-001 Phase 2 Clinical Nanjing Medical University Lymphoma, B-Cell Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase 2 Clinical Bluebird Bio Inc Lymphoma, B-Cell; Leukemia, B-Cell Details
4-1BBz CD19-Her2tG (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Leukemia; Neoplasms; Lymphoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, Non-Hodgkin Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) Phase 1 Clinical Dehe Biotech Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous anti-CD19 CAR T cell therapy(Kyverna Therapeutics) KYV-101 Phase 2 Clinical National Institutes Of Health, Kyverna Therapeutics Inc Myasthenia Gravis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Lupus Nephritis; Scleroderma, Diffuse Details
ISIKOK-19 ISIKOK-19 Phase 2 Clinical Acibadem University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
RG-6333 RO-7443904 Phase 1 Clinical F. Hoffmann-La Roche Ag Lymphoma, Non-Hodgkin Details
PBLTT52CAR19 Phase 1 Clinical Great Ormond Street Hospital For Children Nhs Foundation Trust Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19.CAR T Cells (Heidelberg University Hospital) Phase 2 Clinical Heidelberg University Hospital Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, Non-Hodgkin Details
ET019003-T Cells ET-019003 Phase 1 Clinical Wuhan Union Hospital, Eureka Therapeutics Inc Leukemia; Lymphoma Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
K-193 K-193 Phase 1 Clinical Beijing Lvzhu Biological Technology Co Ltd Lymphoma, B-Cell Details
IKS-03 IKS-03 Phase 1 Clinical Iksuda Therapeutics Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 1 Clinical The First Affiliated Hospital Of Nanchang University Multiple Myeloma Details
CD19 specific Chimeric Antigen Receptor T Cell therapy(Nationwide Children'S Hospital) Phase 1 Clinical Nationwide Children'S Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) Phase 2 Clinical Nanfang Hospital Of Southern Medical University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute Details
Anti-CD19 CAR-T Cells (Shaanxi Provincial People'S Hospital) Clinical Leukemia, B-Cell Details
CD19-STAR-T cell therapy (China Immunotech Co Ltd) Phase 1 Clinical Hebei Yanda Hospital, China Immunotech Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) Phase 1 Clinical University Of Colorado Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) WZTL002-1 Phase 1 Clinical The Malaghan Institute Of Medical Research Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University, Shanghai YaKe Biotechnology Co Ltd Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 UCAR-NK cells(920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) Phase 2 Clinical The 920th Hospital Of Joint Logistics Support Force Of PLA Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 chimeric antigen receptor T cell therapy(TriArm Therapeutics) Phase 1 Clinical TriArm Therapeutics (Shanghai) Co Ltd Hematologic Neoplasms; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) BPX-401 Phase 2 Clinical Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
CTA-30X CTA-30X; CTA30X Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) Phase 1 Clinical Hebei Yanda Ludaopei Hospital Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) Phase 2 Clinical The First Affiliated Hospital Of Soochow University Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Human CD19 Targeted DASH CAR-T Cells (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET190L1-ARTEMI; ET-190; ET190L1; ET190 Phase 1 Clinical Eureka Therapeutics Inc Lymphoma, B-Cell; Leukemia, B-Cell Details
GB5005 chimeric antigen receptor T cell therapy (Genbase) GB-5005 Phase 1 Clinical Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd Leukemia, B-Cell Details
Englumafusp alfa RG-6076; RO-7227166 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
SNUH-CD19-CAR-T Cell Therapy SNUH-CD19-CAR-T Phase 1 Clinical Seoul National University Hospital Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
B-019 B-019 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
MC-19PD1 CAR-T cell therapy (Peking University) Phase 1 Clinical Peking University Lymphoma Details
CD19-7×19 CAR-T(Zhejiang University) Phase 1 Clinical Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
BRL-201 BRL-201; PD1-19bbz; PD1-19bbz CAR-T Phase 2 Clinical Leukemia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD22 dual-target CAR-T (Yake biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CN-201 CN-201 Phase 2 Clinical Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
Anbalcabtagene autoleucel CRC-01 Phase 2 Clinical Curocell Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
QN-019a QN-019a Phase 1 Clinical Hangzhou Qihan Biotechnology Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Bispecific CD19/22 CAR T cells Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) CARCIK-CD19; CIK-CAR.CD19 Phase 2 Clinical Fondazione Matilde Tettamanti Menotti De Marchi Onlus Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CNTY-101 CNTY-101 Phase 1 Clinical Century Therapeutics Llc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
TI-1007 TI-1007 Phase 1 Clinical Tianjin Timmune Biotech Inc Lymphoma, B-Cell Details
EB-103 EB-103 Phase 2 Clinical Estrella Biopharma Inc Lymphoma, B-Cell Details
BinD-19 (Shenzhen BinDeBio) BinD-19 Phase 2 Clinical Shenzhen Bindebio Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) Phase 2 Clinical Beijing Tongren Hospital Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) LNF-1904 Phase 1 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase 1 Clinical Juno Therapeutics Inc Leukemia, Lymphocytic, Chronic, B-Cell Details
BZ019 BZ-019 Phase 2 Clinical Shanghai Cell Therapy Group Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) HX-s001; YTS101; HX-s001/YTS101; HXYT-001 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
AT-101 (AbClon) AT-101 Phase 2 Clinical Abclon Inc Hematologic Neoplasms; Lymphoma, Non-Hodgkin Details
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) Phase 1 Clinical Poseida Therapeutics Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
ALLO-501 ALLO-501 Phase 2 Clinical Cellectis Sa Lymphoma, B-Cell; Lymphoma, Follicular Details
ALLO-501A ALLO-501A Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell Details
ALETA-001 ALETA-001 Phase 2 Clinical Aleta BioTherapeutics Inc Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19- and CD22 specific CAR (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Leukemia; Lymphoma Details
U-01 U-01 Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Leukemia; Leukemia, B-Cell Details
Azercabtagene zapreleucel PBCAR-0191 Phase 2 Clinical Baxalta Incorporated Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin Details
CARTHIAE-1 CARTHIAE-1 Phase 1 Clinical Miltenyi Biotec Inc, Hospital Israelita Albert Einstein Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
GC019F Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Budoprutug Phase 2 Clinical ValenzaBio Inc Nephrosis, Lipoid; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) Phase 1 Clinical Hunan Siweikang Pharmaceutical Co Ltd Multiple Myeloma Details
U-CART (Shanghai Bioray Laboratory Inc) Phase 2 Clinical Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-19 S-68587; UCART-19 Phase 1 Clinical Cellectis Sa Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
GC-502 GC-502 Phase 1 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Phase 1 Clinical Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 2 Clinical The First Affiliated Hospital Of Nanchang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase 2 Clinical Sinobioway Biomedicine Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma Details
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) Phase 1 Clinical Aikangd Biomedical Technology (Suzhou) Co Ltd Leukemia; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin Details
Humanized CD19 CAR-T cell therapy (Yake) YK-C19 Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Murine CD19 CAR-T cell therapy (Yake) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma Details
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) Phase 1 Clinical Tianjin Timmune Biotech Inc Leukemia; Lymphoma, Non-Hodgkin Details
Vadacabtagene leraleucel 19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells Phase 1 Clinical Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
ET-019002 ET-019002 Phase 1 Clinical Eureka Therapeutics Inc Lymphoma, B-Cell; Leukemia, B-Cell Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CC-97540 CC-97540 Phase 1 Clinical Juno Therapeutics Inc Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma Details
Humanized CAR19T2 T Cell therapy(Zhaotai Cell Bio-tech) Phase 2 Clinical Guangdong Zhaotai Cell Bio-tech Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) Phase 1 Clinical Pla General Hospital Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) ssCART-19 Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Co Ltd POEMS Syndrome Details
CLBR-001/SWI-019 CLBR-001/SWI-019 Phase 1 Clinical Abbvie Inc, California Institute For Biomedical Research Lymphoma, B-Cell Details
ICT19G1 ICT-19G1 Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CAR-DC(Zhejiang University) Phase 1 Clinical Zhejiang University Lymphoma, B-Cell Details
Anti-CD19 CAR-T cells with TNFRS19 transmembrane domain Phase 2 Clinical Federal Research Institute of Pediatric Hematology Oncology and Immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
PBCAR19B PBCAR-19B Phase 1 Clinical Baxalta Incorporated, Precision Biosciences Inc Hematologic Neoplasms; Neoplasms Details
IMPT-514 IMPT-514 Phase 2 Clinical ImmPACT Bio USA Inc Lupus Nephritis; Lupus Erythematosus, Systemic Details
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) Phase 1 Clinical Beijing Yongtai Rec Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-Car T Cell Therapy(City Of Hope National Medical Center) Phase 1 Clinical City Of Hope National Medical Center, National Cancer Institute Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma Details
CD19-UCART BRL-301 Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
HY-004 (Juventas) HY-004 (Juventas) Phase 1 Clinical Juventas Cell Therapy Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19 CAR-T cell therapy (National University of Malaysia) Phase 3 Clinical National University Of Malaysia Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
19273-4SCAR 19273-4SCAR Phase 2 Clinical Peking University Lymphoma, B-Cell Details
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells TAK-940 Phase 1 Clinical Takeda, Memorial Sloan Kettering Cancer Center Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma Details
GNR-084 GNR-084 Phase 2 Clinical Generium Pharmaceuticals, Iontas Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) Phase 1 Clinical Memorial Sloan Kettering Cancer Center Leukemia, Lymphocytic, Chronic, B-Cell Details
CART-19 cells (Henan Hualong Biotechnology) Phase 2 Clinical Henan Hualong Biotechnology Leukemia, Lymphoid Details
SYNCAR-001 SYNCAR-001 Phase 1 Clinical Synthekine Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Senl-1904A Senl-1904A; Senl_1904A Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-T 19 cell therapy (University of Pennsylvania) Phase 2 Clinical University Of Pennsylvania Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CAR-NK(JD Biotech) JD-010; JD010 Phase 1 Clinical Beijing JD Biotech Co Ltd Hematologic Neoplasms Details
GLPG-5101 19-CP-02; GLPG5101; 19CP02 Phase 2 Clinical CellPoint BV Lymphoma, Non-Hodgkin Details
KT-030 KT-030 Phase 1 Clinical Nanjing Kati Medical Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
IMPT-314 IMPT-314 Phase 2 Clinical Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan Union Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CAR-T cell therapy (China Immunotech/Avalon Globocare) AVA-001 (Avalon GloboCare); AVA-001 Phase 1 Clinical China Immunotech Co Ltd, Avalon Globocare Corp Lymphoma, B-Cell; Leukemia, B-Cell Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Inc Lymphoma, B-Cell; Leukemia, B-Cell Details
RGV-004 RGV-004 Phase 1 Clinical Hangzhou Rongu Biotechnology Co Ltd Lymphoma, B-Cell Details
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) Phase 1 Clinical Second Affiliated Hospital School Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Denocabtagene Ciloleucel(Beijing Yongtai Ruike Biotechnology Company) RC19D2; CAR-T-19-D2; RC19-D2; CAR-T-19-DNR Phase 2 Clinical Beijing Yongtai Rec Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
1-A-46 BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 Phase 2 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CTL-119 CTL-119 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Multiple Myeloma Details
KUR-502 CD19 CAR-NKT CMD-502; KUR-502 Phase 1 Clinical Athenex Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
TAK-007 TAK-007 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, Non-Hodgkin Details
CC-312 CC-312 Phase 1 Clinical CytoCares (Shanghai) Inc Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
ET-02 ET-02 Clinical Edigene Inc Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu) Lymphoma, Non-Hodgkin Details
CD19-CD34 CAR transduced T cell therapy (Loyola University) Phase 1 Clinical Loyola University Chicago Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CD19 CAR+ EGFTt + T cells (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Leukemia; Leukemia, B-Cell Details
Zeripatamig NI-1701; TG-1801 Phase 1 Clinical Novimmune Sa Lymphoma, B-Cell Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma Details
GC-012F GC-012F; GC012F Phase 2 Clinical Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) Phase 1 Clinical Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital Leukemia Details
CAR-iNKT cells therapy (North Jiangsu People's Hospital) Phase 1 Clinical Affiliated Hospital Of Jiangsu University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Allogeneic CD-19 CAR-T Cell Therapy Phase 2 Clinical Shenzhen University General Hospital Leukemia; Lymphoma, B-Cell Details
Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Leukemia; Lymphoma Details
AUTO-3 AUTO-3 Phase 2 Clinical University College London Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase 2 Clinical Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University Lymphoma, B-Cell; Myasthenia Gravis; Lymphoma, Large B-Cell, Diffuse; Neuromyelitis Optica; Leukemia, B-Cell; Lymphoma Details
BCM-5011 BCM-5011 Clinical ImmuneCyte Inc Lymphoma, B-Cell Details
LCAR-AIO LCAR-AIO; VHH CAR-T Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) Phase 1 Clinical National Cancer Institute Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) Phase 1 Clinical Kunming Medical University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CAR19 T lymphocytes Therapy Phase 1 Clinical Institute of Hematology and Blood Transfusion, Czech Republic Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
YK-012 YK012 Phase 1 Clinical Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd Lymphoma, B-Cell Details
UCART019 UCART-019 Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
KD-019 (Nanjing KAEDI Biotech) KD-C19 (Nanjing KAEDI Biotech) Phase 1 Clinical Nanjing Kaedi Biotechnology Co Ltd Leukemia; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PIT-565 PIT-565 Phase 1 Clinical Novartis Pharma Ag Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) Phase 2 Clinical University Of Alberta Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
FT-819 FT-8198; FT-819; FT 8198 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Allogeneic anti-CD19 CAR T-cell therapy(EdiGene/Peking University/Chinese PLA Hospital) Peking University, Pla General Hospital, Edigene Inc Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd Lymphoma, B-Cell; Glioblastoma Details
NKX-019 NKX-019 Phase 1 Clinical Nkarta Inc Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) RJMty-19 Phase 1 Clinical Zhejiang Ruijiamei Biotechnologies Co Ltd Lymphoma, B-Cell; Autoimmune Diseases; Lupus Erythematosus, Systemic Details
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy GC-197 Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
CAR-T-19(Immunotech Biopharm) CAR-T-19(Immunotech Biopharm) Phase 2 Clinical Immunotech Biopharm Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma Details
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) Phase 2 Clinical Kk Women'S And Children'S Hospital Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) Phase 1 Clinical Sabz Biomedicals Leukemia, Biphenotypic, Acute Details
IASO-782 IASO-782; IASO782 Phase 1 Clinical Shanghai Xunlu Biotechnology Co Ltd Purpura, Thrombocytopenic, Idiopathic; Anemia, Hemolytic, Autoimmune; Thrombocytopenia; Anemia, Hemolytic Details
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) Phase 1 Clinical Zhejiang University, Ningbo Yake Biotechnology Co Ltd Lymphoma Details
Allogeneic Second-generation CD19-CAR T Cells therapy(Bambino Gesu Hospital And Research Institute) Phase 1 Clinical Bambino Gesu Hospital And Research Institute Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
ATA-3219 ATA-3219; ATA3219 Phase 1 Clinical Atara Biotherapeutics Inc Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message